Some exciting news has just been published today about an antiangiogenic compound for cancer patients. Aeterna Laboratories, a Canadian Biotech, released its phase III clinical trial results on renal carcinoma. For a specific subgroup of patients, their product, the Neovastat, increased the median survival time by 109% for patients suffering of clear cell renal carcinoma with 1 metastasis in the lung. These patients more than doubled their life expectancy from 12.6 months for the placebo group to 26.3% for the Neovastat group.
This subpopulation represents some of the "healthier" patients in this study. It seems to confirm the paradigm that the earlier a patient is treated with anti-angiogenic compounds, the better his or her chances for a positive outcome.
Angiogenesis control has been confirmed again to be a promising strategy to fight cancer. While waiting for more pharmaceutical results, there is one dietary supplement on the market with a similar mechanism of action, it's called CarTCell.
[email hidden] (Bill Brown) wrote in :"]news:[email hidden]:
Quoted message said:
Hi,
Some exciting news has just been published today about an antiangiogenic compound for cancer patients. Aeterna Laboratories, a Canadian Biotech, released its phase III clinical trial results on renal carcinoma. For a specific subgroup of patients, their product, the Neovastat, increased the median survival time by 109% for patients suffering of clear cell renal carcinoma with 1 metastasis in the lung. These patients more than doubled their life expectancy from 12.6 months for the placebo group to 26.3% for the Neovastat group.
This subpopulation represents some of the "healthier" patients in this study. It seems to confirm the paradigm that the earlier a patient is treated with anti-angiogenic compounds, the better his or her chances for a positive outcome.
Angiogenesis control has been confirmed again to be a promising strategy to fight cancer. While waiting for more pharmaceutical results, there is one dietary supplement on the market with a similar mechanism of action, it's called CarTCell.
Faithfully yours,
Bill
Please explain how: 1. failure at top line analysis is "promising", and 2. results in a small, statistically insignificant sub-group (N= 3) are meaningful.
[email hidden] (Bill Brown) wrote in message news:<[email hidden]>...
Quoted message said:
Hi,
Quoted message said:
Angiogenesis control has been confirmed again to be a promising
strategy to fight cancer. While waiting for more pharmaceutical results, there is one dietary supplement on the market with a similar mechanism of action, it's called CarTCell.
Faithfully yours,
Bill
Turmeric, the spice is about 40% curcumins, which are a very effective angiogenesis inhibitor. Probably a lot cheaper than a boutique supplement.
